About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: June 2014
Weekly Roundup 6.27.14
Well, I am late again with the Weekly Roundup and I once again seek forgiveness. I didn’t even get much time to tweet! It has been a rowdy few weeks and the summer is shaping up to be unruly. We … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 6.27.14
How a Watch Can Result in More OTC Switches
Remember when your phone was just a phone? You flipped it open and made a call. It also may have told you the time, but you primarily used it for talking to people. Today you actually use it in ways … Continue reading
Posted in OTC Switches
1 Comment
Guidance on Two Social Media Fronts from FDA’s OPDP
For four and half years now FDA’s OPDP has endeavored to devise answers to 5 questions raised during a public hearing on the Internet, Social Media and Pharma and Device Manufacturers held in April 2009. Finally, on a day when … Continue reading
Posted in Social Media
Comments Off on Guidance on Two Social Media Fronts from FDA’s OPDP
Join Me for a Webinar – Communications Implications of the Sunshine Act Data
I don’t usually do adverts here on the blog – in fact never, but you may remember a posting I did a few months back on the communications implications of the Sunshine Act implementation. There is room to be expansive … Continue reading
Posted in Tutorial, Useful Resources
Comments Off on Join Me for a Webinar – Communications Implications of the Sunshine Act Data
Weekly Roundup 6.13.14
It is hot. It is humid. Mosquitoes have begun to make their presence known. Thunder and rain showers occur almost daily. Summer is truly here. And we are making our way rapidly to my favorite day of the year – … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 6.13.14